Delivery Order SPE2DR25D2104-SPE2DR26F3PAV
- Not listed
- The Defense Logistics Agency awarded a $24,702.56 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $13,358.00 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on November 3, 2025, with completion scheduled for November 4, 2025. This firm fixed-price contract, which is not set-aside, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at the...
- The Defense Logistics Agency awarded a $66,161.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on September 11, 2025, with an ultimate completion date of September 12, 2025. This non-set-aside competitive award represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $10,348.50 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on August 21, 2025, with completion targeted for August 22, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems...
- The Defense Logistics Agency awarded a $1,379.80 delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on August 6, 2025, with an ultimate completion date of August 7, 2025. This firm fixed-price contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $6,899 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract requires no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TYPHIM VI is a typhoid conjugate vaccine commonly used for military personnel and federal...
- The Defense Logistics Agency awarded a delivery order valued at $2,759.60 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TYPHIM VI is a typhoid vaccine product, reflecting the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $3,827.28 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on July 31, 2025, with completion targeted for August 1, 2025. This firm fixed price delivery order, awarded without set-aside designation through competitive procurement, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $36,934.42 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on September 22, 2025, with an ultimate completion date of September 23, 2025. This firm fixed price, competitively awarded contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a $16,231.21 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes, with an ultimate completion date of November 10, 2025. This non-set-aside contract was competitively awarded on November 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TYPHIM VI is a typhoid vaccine product, reflecting the company's role as a critical pharmaceutical supplier to...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3PAVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,899.29 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on November 14, 2025, with an ultimate completion date of November 17, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation leverages AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. TYPHIM VI is a typhoid vaccine product, and this procurement supports the federal medical supply requirements across military and veteran healthcare systems. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen maintains extensive capabilities to supply vaccines, medications, and medical devices to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. The company's ongoing engagement as a prime vendor through the DLA's Pharmaceutical Prime Vendor Global Program demonstrates its established role in supporting military medical logistics and readiness initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.9k | 11/14/25 |